Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in…
<!-- Name:DistributionId Value:8809396 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Harpoon Therapeutics
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today…
Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager…
Clinically active and well tolerated in patients with solid tumorsFavorable safety profile emerging: 22% of patients experienced Grade 1-2 cytokine release syndrome (CRS); no Grade 3 or…
Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel…
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today…
Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T…
Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase of ongoing trialsEncouraging profile of tolerability and activity…
Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study…
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma…
Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today…
Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and…
Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate…